These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16140080)

  • 1. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
    D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
    Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
    Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
    Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
    Dowling AJ; Czaykowski PM; Krahn MD; Moore MJ; Tannock IF
    J Urol; 2000 May; 163(5):1481-5. PubMed ID: 10751862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
    Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
    D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
    J Urol; 2005 May; 173(5):1572-6. PubMed ID: 15821488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
    Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW
    Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
    Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
    Miyake H; Hara I; Yamazaki H; Eto H
    Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer.
    Dvorak T; Chen MH; Renshaw AA; Loffredo M; Richie JP; D'Amico AV
    Urology; 2005 Nov; 66(5):1024-8. PubMed ID: 16286117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
    D'Amico AV; Renshaw AA; Loffredo B; Chen MH
    Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
    Semeniuk RC; Venner PM; North S
    Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.
    Oefelein MG; Agarwal PK; Resnick MI
    J Urol; 2004 Apr; 171(4):1525-8. PubMed ID: 15017212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
    Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
    Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
    Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.